HF
CLYM

HRT Financial’s Climb Bio CLYM Stock Holding History

HRT Financial’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
+37,161
New +$214K ﹤0.01% 3020
2025
Q3 		– Sell
-18,529
Closed -$22K – 3866
2025
Q2 		$22K Buy
+18,529
New +$23.1K ﹤0.01% 2395
2021
Q4 		– Sell
-11,797
Closed -$212K – 4235
2021
Q3 		$212K Buy
+11,797
New +$244K ﹤0.01% 2646

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

HRT Financial's CLYM Position: Q1 2026 in Review

HRT Financial opened a new position in Climb Bio (CLYM) in Q1 2026: 37,161 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #3020 among its holdings. This is a return to the name: HRT Financial previously reported a position in CLYM as recently as Q2 2025.

HRT Financial first reported a position in CLYM in Q3 2021 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • HRT Financial held 37,161 shares of Climb Bio worth $254K as of Q1 2026.
  • Climb Bio was a new HRT Financial position in Q1 2026.
  • Climb Bio made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3020 holding.
  • HRT Financial first reported a position in Climb Bio in Q3 2021 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.